Congenital Diaphragmatic Hernia as a Potential Target for Transamniotic Stem Cell Therapy

Preclinical study in a rat model demonstrates that transamniotic stem cell therapy (TRASCET) using amniotic fluid-derived mesenchymal stem cells modulates key growth factor expression in fetuses with congenital diaphragmatic hernia. Treated animals showed significant downregulation of FGF-10 and VEGF-A compared to controls, suggesting potential therapeutic benefit for this challenging prenatal condition.